The outer membrane protein F gene (oprF) of Pseudomonas aeruginosa was recently shown by us to protect mice from P. aeruginosa chronic pulmonary infection when used as a DNA vaccine administered by three biolistic (gene gun) intradermal inoculations given at 2-week intervals. In the present study, we used two different strategies to improve the protective efficacy of the DNA vaccine. In the first strategy, mice were primed with two biolistic intradermal inoculations with the oprF vaccine and then were given a final intramuscular booster immunization containing either a synthetic peptide^keyhole limpet hemocyanin (KLH) conjugate or a chimeric influenza virus. Both the synthetic peptide conjugate and the chimeric virus contained peptide 10, a previously identified immunoprotective epitope of protein F. The second strategy involved the addition of a second outer membrane protein to the vaccine. DNA encoding a fusion protein comprised of the C-terminal half of protein F fused to OprI was administered by three biolistic intradermal inoculations. Challenge with P. aeruginosa in a chronic pulmonary infection model demonstrated that boosting with the chimeric virus (but not with peptide^KLH) or adding oprI to the DNA vaccine significantly enhanced protection as compared to that afforded by the oprF vaccine given alone. Thus, both strategies appear to augment the protection afforded by an oprF-only DNA vaccine. ß
Introduction
Antibiotic resistance has emerged as a major public health threat, due to the overuse of these drugs [1] . Recent reports list Pseudomonas aeruginosa among the most serious antibiotic-resistant bacteria [2, 3] and among the three most frequently reported nosocomial pathogens [4] . P. aeruginosa is important clinically as an opportunistic pathogen that causes acute life-threatening infections, including pneumonia and bacteremia, in compromised individuals such as those with severe burns, with certain cancers, who are elderly, or who are otherwise immunocompromised. It also causes chronic, severe pulmonary infection in cystic ¢brosis patients. The use of antibiotics could be reduced signi¢cantly if e¡ective vaccines were available. The control of infectious diseases requires multiple approaches, but vaccination is an extremely attractive avenue that can induce long-term protection.
Genetic immunization is an attractive recent advance in vaccine development [5] that has been used to elicit protective antibodies and cell-mediated immune responses in a variety of animal models of viral and bacterial diseases [6, 7] . DNA vaccination still represents a relatively novel approach for inducing a speci¢c immune response since the antigen is produced in vivo and is subsequently presented on either MHC-I or MHC-II molecules [8^10] . Most of the work in this area has been in the development of vaccines against intracellular pathogens such as viruses [11^13] , intracellular bacterial pathogens such as Mycobacterium tuberculosis [14^17], or eukaryotic pathogens such as Plasmodium [5] . We recently published the ¢rst report of protection against an extracellular bacterial pathogen by genetic immunization using a DNA vaccine encoding the outer membrane protein F gene (oprF) of P. aeruginosa [18] . This vaccine a¡orded protection upon subsequent challenge with the bacterium in a mouse model of chronic pulmonary infection. Our present objective was to determine if the protective e⁄cacy of this DNA vaccine could be augmented by altering the immunization strategy. We report here two approaches that enhance the overall protective e⁄cacy of DNA-based vaccination against P. aeruginosa. The ¢rst approach involved altering the immunization protocol to include two biolistic intradermal (i.d.) inoculations with the oprF DNA vaccine followed by a ¢nal intramuscular (i.m.) booster immunization with a chimeric Pseudomonas-in£uenza virus displaying an insert of the peptide 10 epitope of OprF within its hemagglutinin (HA) protein. The second approach involved altering the composition of the DNA vaccine to consist of DNA encoding the C-terminal half of OprF fused to OprI. Both approaches were successful in enhancing the protection a¡orded by OprF-based DNA vaccination against subsequent challenge with P. aeruginosa in a mouse model of chronic pulmonary infection.
Materials and methods

Plasmid construction
The eukaryotic expression plasmid, pVR1020 (Vical, Inc., San Diego, CA, USA), was used in this study. This plasmid contains an immediate-early cytomegalovirus promoter to ensure e⁄cient expression in a eukaryotic host, as well as the human tissue plasminogen activator secretion signal to facilitate secretion of the target antigen from the eukaryotic cell [19, 20] . Construction of the pVR1020/ oprF has been described previously [18] . The 669-bp oprF/I fusion gene, encoding amino acids (aa) 190^342 of OprF fused to aa 21^83 of OprI [21] , was cloned from a pET22b expression vector [21, 22] using a Qiagen Taq polymerase core kit (Qiagen, Inc., Santa Clarita, CA, USA) with primers engineered to contain BamHI and BglII cut sites at the 5P-and 3P-ends, respectively. This PCR product and pVR1020 were digested with BamHI and BglII. The plasmid was subsequently de-phosphorylated with calf-intestinal alkaline phosphatase, and the resulting products were ligated with T4 DNA ligase (Life Technologies, Gaithersburg, MD, USA). The resulting plasmid, pVR1020/oprF/I, was transformed into Escherichia coli DH5K, puri¢ed by anion-exchange chromatography using Qiagen-tip 2500 (Qiagen, Inc.), and resuspended in cell culture-grade phosphate-bu¡ered saline (PBS) (Life Technologies) to a ¢nal concentration of 1 mg ml 31 .
Immunization protocol
Mice (5 weeks old, female, speci¢c-pathogen-free, ICR strain) were obtained from Harlan^Sprague^Dawley, Indianapolis, IN, USA. These mice were housed in the Animal Resources Facility at LSUHSC-S and handled according to American Association for Laboratory Animal Sciences (AALAS) guidelines. Groups of 20 mice were inoculated at 14-day intervals a total of three times in the abdomen via biolistic particle injection (Bio-Rad Helios Gene Gun kit, Bio-Rad, Richmond, CA, USA) with 2 Wg of either pVR1020 (control), pVR1020/oprF, or pVR1020/oprF/I coated onto 1 Wm gold beads. Two other groups of mice were inoculated two times at 14-day intervals in the abdomen via biolistic particle injection with the pVR1020/oprF vaccine as above, but followed by a ¢nal i.m. boost of either peptide 10^keyhole limpet hemocyanin (KLH ; 50 Wg in 0.1 ml of PBS, pH 7.2) or 10 5 plaque-forming units (pfu) of chimeric HG10-11 virus (chimeric in£uenza virus expressing an 11-mer of peptide 10 in an immunodominant domain of its HA). Serum samples were taken from each immunized group on days 28 (two mice bled) and 42 (three mice bled), with the remaining 15 mice in each group used in challenge experiments.
In vitro expression in eukaryotic cells
Expression from the DNA vaccine constructs was veri¢ed in transient transfection assays using human melanoma UM449 cells. Cells were transfected in duplicate with 2 Wg of either pVR1020, pVR1020/oprF, or pVR1020/ oprF/I. Following 48 h incubation, the culture medium was removed from the UM449 cell layers and the supernatants resulting from centrifugation (10 000Ug for 10 min at 4 ‡C) of that culture medium were used for immunoblot analysis to detect in situ synthesis and secretion of OprF from pVR1020/oprF or OprF/I fusion protein from pVR1020/oprF/I. The cell layer was washed once in PBS. The cells were resuspended in PBS and lysed in SDSP AGE sample bu¡er prior to use in the immunoblot analysis. The immunoblot protocol has been described previously [23] .
Bacterial strains used
All bacterial strains were grown routinely at 30 
Virus propagation
The chimeric HG10-11 in£uenza virus and its parent WSN in£uenza virus have been described previously [24] and were each propagated in Madin^Darby canine kidney cells.
Analysis of antibody speci¢city by immunoblot and by ELISA
Polyclonal antisera speci¢city was analyzed by immunoblot against P. aeruginosa PAO cell lysates using a previously described method [25] . Nitrocellulose membranes were blocked in 2% (w/v) nonfat milk in 0.1% Tween 20 with Tris-bu¡ered saline (TBST), and probed with polyclonal mouse sera from the vaccinated mice. The membrane was washed three times in TBST, and rabbit antimouse IgG conjugated to horseradish peroxidase (Amersham Life Science, Arlington Heights, IL, USA) was added as a secondary antibody. Reactive polypeptides were detected using a chemiluminescent substrate (National Diagnostics, Inc., Atlanta, GA, USA) and visualized on ¢lm.
Sera recovered from the various groups of vaccine-immunized and control mice were analyzed by ELISA for reactivity against bacterial cells, peptide 10^14-mer [26] , puri¢ed protein F [27] , and the WSN and HG10-11 viruses [24] according to published procedures [26, 27] . The wells of microtiter plates (polyvinyl chloride or Dynatech, Immulon 4) were coated with either approximately 5U10 6 bacterial whole cells of KG1077 or each FD immunotype strain, 2.5 Wg of synthetic peptide 10^14-mer, 10 Wg of protein F, or approximately 10 4 pfu of the appropriate virus. Dilutions of sera pooled from like-immunized mice were incubated with the prepared microtiter plate at 37 ‡C for 1 h. Bound IgG was detected by alkaline phosphataseconjugated goat anti-mouse IgG (Southern Biotechnology Assoc. Inc., Birmingham, AL, USA) using p-nitrophenyl phosphate (Sigma-Aldrich, St. Louis, MO, USA) as the substrate. Endpoint titers for P. aeruginosa whole cell-, peptide 10-, protein F-, or virus-speci¢c antibodies were expressed as the inverse of the dilution that gave a mean OD 405 twice that of an OD 405 of a 1:50 dilution of normal mouse sera obtained from unimmunized mice. All sera were analyzed in at least two separate assays.
Analysis of antibody isotype response
Antibody isotypes were analyzed by ELISA as previously described [28] as modi¢ed by Abdillahi et al. [29] . Brie£y, Immulon 3 plates (Dynatech Laboratories, Inc., Chantilly, VA, USA) were coated with 100 ng of gel-puri¢ed OprF [27] suspended in PBS. Plates were then placed at 37 ‡C overnight to allow the bu¡er to evaporate. Serum samples were diluted 1:50 in PBS containing 0.025% Tween 20 and added to the plate. Serial dilutions were performed in the 96-well plate; anti-mouse IgG 1 , antimouse IgG 2a , or anti-mouse IgA conjugated to alkaline phosphatase were used as the secondary antibody (Zymed Laboratories, Inc., San Francisco, CA, USA). Bound antibody was detected using p-nitrophenyl phosphate (Sigma) as the substrate and quantitated by optical density read at 410 nm using a Dynatech MR600 plate reader against a standard curve obtained with puri¢ed IgA, IgG 2a and IgG 1 antibody reagents (Zymed Laboratories, Inc.).
Assay for opsonization by antisera
Sera taken 14 days after the last immunization from the various groups of vaccine-immunized mice and from control mice were tested for the ability to mediate the opsonophagocytic uptake of P. aeruginosa by human polymorphonuclear leukocytes (PMNs) as described previously [30] . All sera were heated at 56 ‡C for 30 min to inactivate complement. Cultures of the FD immunotype 4 strain were diluted to a cell density of 10 8 cells ml 31 for use in the assay. The reaction mixtures included 50 Wl of bacterial culture plus 50 Wl of serum. These mixtures were incubated for 30 min at 37 ‡C with shaking. Then, 100 Wl of human venous blood was added to each mixture, and this ¢nal combination was incubated for 30 min at 37 ‡C with shaking. Blood smears were prepared from each of the reaction mixtures and stained with Giemsa stain. For each assay three slides per reaction mixture were examined microscopically, and the number of bacterial cells contained within the ¢rst 75 isolated, intact PMNs encountered (25 PMNs per slide) was determined for each reaction mixture. Each assay was performed in duplicate. The mean number of bacterial cells per PMN was calculated, and then an opsonic ratio for each reaction mixture was calculated. The opsonic ratio represents the mean number of bacteria associated per PMN with the test sera divided by the mean number of bacteria associated per PMN with control sera.
Assay for immunoprotection upon active immunization
The immunoprotective potential of the DNA vaccine was tested in a mouse model of chronic pulmonary infection [24,31^33] . Two weeks after the ¢nal immunization, all groups of mice were challenged with agar beads containing P. aeruginosa cells of the FD immunotype 4 strain. The mice were ¢rst anesthetized with an intraperitoneal injection of sodium pentobarbital and then inoculated via a tracheal incision with 50 Wl of an agar bead slurry encasing approximately 1.5U10 3 colony-forming units (CFU) of P. aeruginosa. A beaded-tip 22-gauge needle was gently guided to favor inoculation of the left lung. The incision was closed with sterile wound clips. Eight days after the challenge, protection a¡orded to the immunized mice by the DNA vaccine was assessed by two methods. First, the lungs were examined macroscopically for the presence of lesions [24, 31, 32] . Lesions were scored as 0 to 4+ as follows : 0, absence of any macroscopic lesion; 1+, presence of one or two small lesions not exceeding 1 mm in diameter ; 2+, presence of three or more small lesions not exceeding 1 mm in diameter; 3+, presence of a medium lesion 2^5 mm in diameter ; 4+ presence of a large lesion exceeding 5 mm in diameter. Scoring of the pulmonary lesions was performed by an investigator with more than 15 years experience in macroscopic lung lesion scoring. Lesions scored as 2+ to 4+ were considered to be severe lesions. Second, bacterial quantitation of the number of P. aeruginosa present in the lungs was performed as described previously [24, 31, 32] . Brie£y, both lungs were aseptically removed and homogenized in a 1:10 (w/v) dilution of sterile saline with a tissue grinder. Dilutions of these lung tissues were plated onto nutrient agar for quantitative determination of the numbers of Pseudomonas present [24] . Duplicate challenge experiments were performed and the results compiled for analysis.
Assay for passive immunoprotection
BALB/c mice (4^5 weeks old, female, Jackson Laboratories, Bar Harbor, ME, USA) were housed in the animal resources facility at OSU and handled according to AA-LAS guidelines. P. aeruginosa FD4 was grown for 18 h in LB broth, washed three times in PBS, and resuspended in PBS at an optical density of 0.2 at 600 nm. This corresponded to approximately 2 LD 50 of bacteria suspended in 50 Wl of PBS. 10 Wg of polyclonal antisera from each of the following groups of immunized mice (pVR1020, 3U; pVR1020/oprF, 3U; pVR1020/oprF, 2U, HG10-11, 1U; pVR1020/oprF/I, 3U) were mixed with the bacteria and incubated at 37 ‡C for 30 min. These suspensions were then administered intranasally (50 Wl/mouse) to groups of ¢ve mice, and mortality was monitored for 10 days.
Statistical analysis
Statistical analyses of the di¡erences in the number of mice with severe lung lesions and in bacterial clearance between mice in the various immunization groups were performed with the IBM EpiStat Basic Statistics program. P values were calculated by the Fisher exact test, with P values of 9 0.05 considered to be signi¢cant.
Results
Production of OprF and OprF/I by eukaryotic cells
To verify expression of the target genes and synthesis of the target proteins in mammalian cells, immunoblot analysis of transfected cells was performed. The adherent human melanoma cell line UM449 was transiently transfected with plasmid pVR1020/oprF, pVR1020/oprF/I, or pVR1020 (negative control), and after a 48-h incubation, both culture supernatants and cell lysates were examined by immunoblotting with antisera to OprF. Following transfection of UM449 cells with pVR1020/oprF, the protein was found predominantly within the UM449 cells, but was also observed in the supernatant fraction since the pVR1020 plasmid includes a N-terminal secretion signal sequence to facilitate translocation of the OprF to the endoplasmic reticulum and release from the cell (Fig. 1) . Signi¢cantly, analysis of the pVR1020/oprF/I-transfected cells revealed a substantial increase in the proportion of OprF/I that was present in the culture supernatant fraction, accompanied by a lower proportion of OprF/I that remained associated with the cellular fraction of the UM449 cells (Fig. 1). 
Characterization of the antibody response
Antisera from all vaccinated and control groups were evaluated by immunoblot analysis to determine the speci¢city against outer membrane proteins of P. aeruginosa. As seen in Fig. 2 , sera from all three groups of mice vaccinated with the oprF gene reacted speci¢cally with protein F and protein H [18] . Cross-reaction with protein H has been shown previously with sera from mice immunized with protein F [27, 34] . However, OprF has been reported recently [35] to release a degradative C-terminal fragment of 20 kDa. This fragment would run at approximately the same location as OprH on a gel following electrophoresis, which could now explain the apparent cross-reactivity reported between OprF and OprH. Sera from the group of mice receiving the OprF/I fusion protein DNA vaccine reacted with protein I in addition to the F and H proteins (Fig. 2) . The extra band in the blots with pVR1020/oprF/I-sera and pVR1020/oprF, 2U; pep10K LH, 1U-sera is presumed to be a degradative product of OprF. Antibody responses induced by gene-gun inoculation have previously been shown to be predominantly of the IgG 1 isotype, suggesting that a Th2 (humoral) type of immune response was induced [25,36^38] . In the present study gene-gun inoculation of DNA also resulted in a predominant IgG 1 antibody response (Table 1) . Both groups that received all three inoculations by gene gun had ratios of IgG 1 /IgG 2a three-to ¢ve-fold greater than the two groups that received their third immunization by i.m. inoculation of peptide 10^KLH, or HG10-11 chimeric virus, indicating that a more pronounced humoral response was elicited in the two former groups. Levels of IgG antibodies did not correlate speci¢cally with the level of protection achieved by each of the vaccines. Although increased protection (see below) over that provided by the pVR1020/oprF vaccine was noted in both the pVR1020/ oprF/I-vaccinated group and the group immunized with pVR1020/oprF and boosted with the HG10-11 chimeric virus, the levels of IgG 1 and IgG 2a were increased in the pVR1020/oprF/I group but were decreased in the HG10-11-boosted group (Table 1) . There was no signi¢cant increase in the levels of serum IgA antibody in any of the immunized groups versus vector-immunized mice. Thus, the level of protection a¡orded could not be correlated solely with either titer, or isotype, of antibodies elicited.
The titers of IgG antibodies in the sera from the various vaccine groups were determined by ELISA against a panel of antigens ( Table 2 ). The sera from the vector controlimmunized mice did not react (titers of 0^100) with any of the whole cells of the various strains of P. aeruginosa, nor with peptide 10, puri¢ed protein F, or the two in£uenza viruses (WSN or the HG10-11 chimeric virus). The sera from mice biolistically immunized with the pVR1020/oprF vaccine for all three inoculations reacted strongly with whole cells of each of the seven FD immunotype strains, as illustrated for the FD2, -4, and -7 (PAO) immunotypes in Table 2 . The sera did not react signi¢cantly (titers of 100) with the protein F-de¢cient KG1077 strain. This vaccination protocol elicited high titers against protein F, peptide 10 and the HG10-11 chimeric virus containing a peptide 10 insert. Mice that were initially immunized twice with the pVR1020/oprF vaccine and then were boosted with peptide 10^KLH produced sera that reacted with the whole cells of the FD2, -4, and -7 (PAO) strains and with puri¢ed protein F at a titer lower than that seen with the mice that received three inoculations of the pVR1020/ oprF vaccine. These sera also reacted weakly with both peptide 10 and HG10-11. Sera from mice that were primed with two inoculations of pVR1020/oprF and given a ¢nal boost with the HG10-11 chimeric virus produced a similar response, but did react at high titer with the HG10-11 and WSN viruses. However, sera from mice immunized with three inoculations of the pVR1020/oprF/I vaccine demonstrated increased titers against the whole cells of strains FD2, FD4, and PAO (titers of 51 200, 102 400, and 102 400, respectively) and against puri¢ed protein F (titer of 102 400). These antisera also reacted strongly with the peptide 10 epitope, presented as either synthetic peptide 10 or as expressed in the chimeric HG10-11 virus. These sera were the only sera to react strongly with the protein Fde¢cient cells, presumably due to a reaction with protein I in such cells.
Opsonic activity of the antisera
The opsonic activity of sera from the various vaccine groups was quite similar. The opsonic ratios obtained were as follows : for the group vaccinated with three inoculations of pVR1020/oprF, the ratio was 1.33; for the group vaccinated twice with pVR1020/oprF followed by a ¢nal peptide 10^KLH boost, the ratio was 1.02; for the group vaccinated twice with pVR1020/oprF followed by a ¢nal HG10-11 chimeric virus boost, the ratio was 1.47; and for the group vaccinated three times with pVR1020/oprF/I, the ratio was 1.22.
Protection in the murine chronic pulmonary infection model
The immunoprotective potential of the various vaccine protocols used for active immunization was tested in a mouse model of chronic pulmonary infection. Eight days after challenge of the mice with approximately 1.5U10 3 agar-encased FD4 P. aeruginosa cells delivered via intratracheal inoculation into the left lung of each mouse, the lungs were removed and examined for evidence of vaccine protection by two means. First, the presence of severe lung lesions, i.e. lesions scored as being v 2+, was determined (Table 3) . Although the presence of severe lung lesions was reduced in mice receiving the three doses of pVR1020/ oprF, as well as in mice receiving the two doses of pVR1020/oprF followed by boosting with the peptide 10^KLH conjugate, the reductions were not statistically signi¢cantly di¡erent than the number of severe lesions observed in the control group (Table 3) . By contrast, statistically signi¢cant (P = 0.001 and 6 0.0001, respectively) reductions in the number of severe lung lesions versus the number of severe lesions observed in the control group were elicited by the vaccine protocols that included either boosting intramuscularly with the HG10-11 chimeric virus after priming with two i.d. injections of pVR1020/oprF or immunizing with three inoculations of pVR1020/oprF/I. Furthermore, the level of reduction a¡orded (severe lung lesions in only 24% of the challenged mice) by the immunization protocol using three inoculations with pVR1020/ oprF/I represented statistically signi¢cantly enhanced (P = 0.028) reduction over the level of reduction (severe lung lesions in 53.8% of the challenged mice) observed with the protocol using the three inoculations with pVR1020/oprF. The level of protection a¡orded (severe lung lesions in only 31% of the challenged mice) by the protocol using the ¢nal boost with the HG10-11 virus was substantially greater than that provided by the pVR1020/ oprF protocol, but it did not quite reach statistical signi¢-cance (P = 0.075; Table 3 ). The lungs were assayed also for the number of mice having sterile lungs 8 days following challenge (Table 4) . Neither of the vaccine groups using either the three doses of pVR1020/oprF or the two doses of pVR1020/oprF followed by the ¢nal boost with peptide 10^KLH had a statistically signi¢cant increase in the number of mice having sterile lungs compared to the control group. In contrast, both immunization protocols using either two doses of pVR1020/oprF followed by HG10-11 boost or three doses of pVR1020/oprF/I had a statistically signi¢cant (P = 0.038 and 0.035, respectively) increase in the number of mice that completely cleared the bacteria from their lungs compared to the control group (Table 4) . These latter two groups also displayed increased clearance of the bacteria from the challenged lungs versus that provided by the pVR1020/oprF vaccine (P = 0.050 and 0.045, respectively, Table 4 ). Immunization with plasmid DNA encoding the C-terminal half of OprF fused to OprI as an i.d. vaccine or immunizing with the oprF DNA vaccine twice intradermally followed by a ¢nal i.m. boost using the chimeric HG10-11 in£uenza virus signi¢cantly augmented the level of protection a¡orded over that provided by three i.d. inoculations with the oprF DNA vaccine (Table 4).
Passive protection with antisera
A passive-protection experiment was performed to determine if protection could be mediated by antisera in a model of acute lung infection. Sera with higher titers (Table 2) of anti-Pseudomonas whole cell-reactive antibodies (pVR1020/oprF/I, 3U-and pVR1020/oprF, 3U-immunized mice) gave better protection than sera (pVR1020/ oprF, 2U, HG10-11, 1U group) with lower titers of whole cell-reactive antibodies. In the two groups of mice that had similar high-level protection upon active immunization, the antisera from the pVR1020/oprF/I-immunized group mediated signi¢cant passive protection, whereas the antisera from the pVR1020/oprF, 2U, HG10-11, 1U-immunized group provided no protection (Table 5 ).
Discussion
Our laboratory has been examining the use of protein F (OprF) from the outer membrane of P. aeruginosa as a protective vaccine. We have used a number of rodent models of infection [24, 27, 31, 39, 40] with P. aeruginosa to demonstrate the protective e⁄cacy of protein F in various forms. These include the use of the puri¢ed protein [27, 31, 39, 41] , synthetic peptides coupled to a carrier protein [26, 40, 42] , a chimeric virus engineered to contain one or two epitopes of protein F within a viral surface protein Table 5 Protection a¡orded upon passive administration of the various antisera [ 24, 32, 43, 44] , and ¢nally, use of the oprF gene as a DNA vaccine [18] . In this report we demonstrate that alterations in the immunization protocol used for genetic immunization against OprF signi¢cantly augment the level of protection provided by the DNA vaccine.
In our initial report of protective e⁄cacy with a DNA vaccine, an expression plasmid containing the oprF gene a¡orded signi¢cant protection in the murine chronic pulmonary infection model following immunization with a series of three biolistic (i.d.) inoculations (but not following immunization with a series of three i.m. injections) [18] . The oprF vaccine provided signi¢cant protection not only against the development of severe lung lesions (present in 43% of vaccinated mice versus in 76% of control mice; P = 0.002) but also by promoting the clearance of the inoculated challenge organisms (sterile lungs in 50% of vaccinated mice versus in 29% of control mice; P = 0.035). From that study it was apparent that the route of immunization (i.d. by gene-gun versus i.m. injection) dramatically a¡ected the e⁄cacy of the DNA vaccine. Therefore, we decided to determine whether the level of protection provided by the oprF DNA vaccine could be enhanced further by alteration of the immunization protocol or the vaccine content.
Signi¢cantly, in the experiments described in this report, the mouse chronic pulmonary infection model used a P. aeruginosa challenge dose that was two-fold greater than that used in our previous study (1.5U10 3 CFU vs. 7.1U10 2 CFU). In the present study two di¡erent active immunization strategies yielded signi¢cantly increased protection over that a¡orded by the oprF vaccine delivered by three i.d. inoculations as described in our previous report [18] . The ¢rst approach utilized a prime-boost strategy using two i.d. pVR1020/oprF DNA inoculations delivered by gene gun followed by a ¢nal i.m. inoculation using a chimeric virus with an OprF protective epitope on its surface. The second approach consisted of three i.d. inoculations with a plasmid DNA vaccine encoding an OprF/I fusion protein.
We observed signi¢cantly increased protection using a prime-boost approach when the third inoculation was given as an i.m. injection of the HG10-11 chimeric in£uenza virus ( Table 3 ). The percentage of mice that had severe lung lesions at 8 days post-challenge fell from 77.8% in the control group to 53.8% in the oprF-vaccinated group receiving the three i.d. inoculations (P = 0.060 vs. control group) and to only 31% in the group receiving the ¢nal boost by i.m. injection of the HG10-11 virus (P = 0.001 vs. control group, P = 0.075 vs. oprF group). Furthermore, the percentage of mice that had completely cleared their lungs of the challenge organisms at day 8 was 33.3% in the control group, 34.6% in the group receiving three i.d. inoculations of the oprF vaccine, but 60.7% in the group receiving the ¢nal boost by i.m. injection of the HG10-11 virus (P = 0.038 vs. control, P = 0.050 vs. the group vaccinated with three i.d. inoculations, Table 4 ). Thus, delivering the third (¢nal) immunizing dose as an i.m. injection of the chimeric virus resulted in a substantial increase in the protection a¡orded by the oprF DNA vaccine. Using DNA immunization to prime the immune system, followed by a heterologous boost, such as a chimeric virus, protein, or peptide, has been shown previously [45^47] to improve the e⁄cacy of DNA vaccines.
The mechanism responsible for the substantial augmentation of protection observed in this prime-boost experiment remains uncertain. Surprisingly, boosting with peptide 10 coupled to the KLH carrier protein did not result in a signi¢cant increase in protection (Tables 3 and 4) . Peptide 10, a linear epitope of OprF that is 14 aa in length representing residues 305^318 (NATAEGRAINRRVE) of the mature protein, has previously been shown to protect when used as an immunogen [26, 40, 42] . The HG10-11 virus is a chimeric in£uenza virus expressing an 11-aa portion (AEGRAINRRVE) of the peptide 10 epitope in the antigenic B site of its HA surface protein. Previous studies have reported that immunization with multiple doses of the HG10-11 chimeric virus results in protection in this model [24, 44] . A single inoculation with the HG10-11 virus does not a¡ord protection, nor elicit antibodies at signi¢cant levels (unpublished observations). Interestingly, using either peptide 10^KLH or HG10-11 chimeric virus in these prime-boost experiments did not result in any increase in antibody titers (Tables 1 and 2 ), suggesting that boosting with peptide 10 presented in these con¢gu-rations was ine¡ective at inducing increased antibody titers. This was also supported by the lack of any increased opsonophagocytic response. Finally, the failure of antisera from HG10-11-boosted mice to provide passive protection (Table 5) indicated that the protection seen in this group upon active immunization (Tables 3 and 4) is not mediated by a humoral response.
The second strategy involved the addition of a second outer membrane protein to the protein F vaccine. We chose to include OprI since the vaccine potential of OprI alone [48] or as a fusion protein [21, 22] with the C-terminal half of protein F has been previously demonstrated. We inserted the DNA sequence specifying the hybrid fusion protein consisting of aa 190^342 of OprF and aa 21^83 of OprI into pVR1020 for use as a genetic vaccine. Three i.d. inoculations of the oprF/I vaccine resulted in clearly superior protection compared to immunization with the oprF vaccine. Compared to the 77.8% of control mice having severe lung lesions at 8 days post-challenge, the oprF/I-vaccinated group had only 24% with severe lung lesions (P = 6 0.0001), whereas the oprF-vaccinated group had 53.8% with severe lung lesions (P = 0.060). This decrease (from 53.8 to 24%) represents a statistically signi¢cant (P = 0.028) increase in protection by the oprF/I vaccine over the oprF vaccine. The oprF/I vaccine likewise provided signi¢cantly increased (P = 0.045) lung clearance over that provided by the oprF vaccine (62.5% with sterile lungs vs. 34.6%, respectively).
The increased protective ability of the oprF/I vaccine compared to the oprF vaccine may be due in part to the presence of antibodies directed against the second immunogen (OprI) (see Fig. 2 ). Sera from the oprF/I-vaccinated mice reacted at higher IgG titers with whole cells of various strains of P. aeruginosa and reacted with the OprFde¢cient strain, which indicates that OprI is being recognized by these sera. However, the oprF/I sera also reacted at higher titers with puri¢ed protein F, with synthetic peptide 10, and with the HG10-11 virus carrying an insert of peptide 10. This would not be due to anti-OprI antibodies but may indicate higher levels of IgG antibodies were elicited by this vaccine that react speci¢cally with OprF or selected OprF epitopes (Tables 1 and 2 ). The increased serum antibody titers may be due to di¡erences in the presentation of conformational epitopes of the OprF portion of the fusion F/I protein compared with OprF alone, to increased stability of the hybrid OprF/I protein upon expression [21, 22] , or to more e⁄cient secretion of the F/I fusion protein from host cells (Fig. 1) , thereby resulting in a better presentation to the immune system of the host. However, despite the higher titers of reactive IgG antibodies present in the OprF/I sera, we did not observe any signi¢cantly increased opsonic activity in the sera from OprF/I-vaccinated mice. Nevertheless, and most importantly, protection could be passively transferred using sera from the pVR1020/oprF/I-vaccinated mice. Our results indicate that antibody-mediated immunity is the principal factor in the protective response observed in pVR1020/oprF/I-vaccinated mice.
Each strategy (prime-boost approach of priming immunizations with pVR1020/oprF DNA followed by boost with the chimeric HG10-11 virus or approach of immunizations with pVR1020/oprF/I DNA) yielded a level of protective e⁄cacy that compares favorably with that previously seen using protein F itself puri¢ed from the outer membrane of P. aeruginosa. A compilation of data from three previously published studies [31, 41, 49] using protein F as a vaccine in the rodent chronic pulmonary infection model revealed that, compared to control-immunized animals which had severe lesions present in the lungs of 71.6% (139/194) of the group with only 23% (14/60) having sterile lungs, protein F-immunized animals had 28.6% (52/ 182) with severe lesions present in the lungs and 59% (35/ 59) with sterile lungs upon bacterial quantitation of the number of P. aeruginosa present in the lungs. The results from the present study (Tables 3 and 4) indicate that a DNA vaccine holds promise for providing protection at an equivalent level to that provided by the puri¢ed protein itself.
In this study we have demonstrated that the protective e⁄cacy of a DNA vaccine based upon OprF of P. aeruginosa as the target immunogen can be substantially enhanced by either of two di¡erent strategies. The ¢rst uses a prime-boost approach using a chimeric in£uenza virus containing the immunoprotective peptide 10 epitope of OprF as the protein boost. Enhanced protection in this case may be the product of increased T-cell immunity since passive transfer of sera failed to transfer protection. The second approach uses a gene-fusion construct consisting of oprI fused in frame with that of a fragment of oprF, resulting in a DNA vaccine targeting two outer membrane proteins. Our results indicate that this vaccine produces signi¢cantly enhanced protection in a chronic pulmonary infection model, apparently due to an enhanced antibody response which could be passively transferred. The successful use of these strategies strongly supports the continued development of an OprF-based DNA vaccine for immunotherapy in humans.
